Aspire Biopharma Holdings, Inc.ASBP
Price (close)
$8.32
Market cap
$11.7M
P/E
—
Revenue (TTM)
$97,659
Net income
-$11.0M
Dividend yield
—
1-year total return
-45.0%
Net margin
-11314.1%
Revenue growth
—
Debt / equity
—
What Aspire Biopharma Holdings, Inc. does.
is an early-stage biopharmaceutical company. As a Delaware corporation formed in February 2025, the Company engages in the business of
developing and marketing the disruptive technology for novel sublingual delivery mechanisms initially for known drugs. Prior to our Business
Combination we were a privately held Puerto Rico corporation incorporated in September 2021. Our internet address is www.aspirebiolabs.com.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $6,202 |
| Net income | — | $3.3M | $4.5M | -$1.3M | -$24.5M |
More on ASBP.
- Aspire Biopharma Holdings, Inc. summary
- Aspire Biopharma Holdings, Inc. financial statements
- Aspire Biopharma Holdings, Inc. key metrics
- Aspire Biopharma Holdings, Inc. health scores and style box
- Aspire Biopharma Holdings, Inc. earnings
- Aspire Biopharma Holdings, Inc. dividends
- Aspire Biopharma Holdings, Inc. valuation
- Aspire Biopharma Holdings, Inc. ownership and insiders
- Aspire Biopharma Holdings, Inc. peers
Figures from Aspire Biopharma Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.